Immunity to polio, measles and rubella in women of child-bearing age and estimated congenital rubella syndrome incidence, Cambodia, 2012

Epidemiology and Infection

Volumn 143, Issue 9, 2015, Pages 1858-1867

  Mao, B ^a   Chheng, K ^b   Wannemuehler, K ^c   Vynnycky, E ^d,e   Buth, S ^b   Soeung, S C ^f   Reef, S ^c   Weldon, W ^g   Quick, L ^c   Gregory, C J ^c  

^a UNIVERSITY OF HEALTH SCIENCES   (Cambodia)

^b National Institute of Public Health   (Cambodia)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Ministry of Health Cambodia   (Cambodia)

^g NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Congenital (intrauterine) infection; epidemiology; measles (rubeola); polio; rubella

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DISABILITY ADJUSTED LIFE YEAR; ECONOMIC EVALUATION; HEALTH CARE COST; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MALARIA; OUTCOME ASSESSMENT; PARASITE LOAD; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; QUALITY OF LIFE; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADULT; AGE; CAMBODIA; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; FEMALE; IMMUNOLOGY; INCIDENCE; MEASLES; MEASLES VIRUS; PHYSIOLOGY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREVALENCE; RUBELLA; RUBELLA SYNDROME, CONGENITAL; RUBELLA VIRUS; VIROLOGY; YOUNG ADULT;

VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CAMBODIA; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INCIDENCE; MEASLES; MEASLES VIRUS; POLIOMYELITIS; POLIOVIRUS; PREVALENCE; RUBELLA; RUBELLA SYNDROME, CONGENITAL; RUBELLA VIRUS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84930272969     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814002817     Document Type: Article

References (39)

1. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2013 global summary (http://apps.who.int/immunization-monitoring/globalsummary/countries). Accessed 6 March 2014.
2. National Institute of Statistics, Directorate General for Health, and ICF Macro, 2011. Cambodia Demographic and Health Survey 2010. Phnom Penh, Cambodia and Calverton, Maryland, USA: National Institute of Statistics, Directorate General for Health, and ICF Macro.
3. Luo HM, et al. Identification and control of a poliomyelitis outbreak in Xinjiang, China. New England Journal of Medicine 2002; 369: 1981-1990.
4. Centers for Disease Control and Prevention. Poliomyelitis outbreak - Republic of the Congo, September 2010-February 2011. Morbidity and Mortality Weekly Report 2011; 60: 312-313.
5. Lowther SA, et al. World Health Organization regional assessments of the risks of poliovirus outbreaks. Risk Analysis 2013; 33: 664-679.
6. Prevots DR, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clinical Infectious Diseases 1998; 26: 419-425.
7. Centers for Disease Control and Prevention. Outbreak of poliomyelitis - Cape Verde, 2000. Morbidity and Mortality Weekly Report 2000; 49: 1070.
8. Centers for Disease Control and Prevention. Outbreak of polio in adults - Namibia, 2006. Morbidity and Mortality Weekly Report 2006; 55: 1198-1201.
9. Centers for Disease Control and Prevention. Outbreaks following wild poliovirus importations - Europe, Africa, and Asia, January-September 2009. Morbidity and Mortality Weekly Report 2010; 59: 1393-9.
10. Khetsuriani N, et al. Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010. Vaccine 2013; 31: 4911-4916.
11. World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record 2011; 86: 301-316.
12. Miyakawa M, et al. Seroprevalence of rubella in cord blood of pregnant women and congenital rubella incidence in Nha Trang, Vietnam. Vaccine 2014; 32: 1192-1198.
13. Caidi H, et al. Rubella seroprevalence among women aged 15-39 year in Morocco. Eastern Mediterranean Health Journal 2009; 15:526-531.
14. Malakmadze N, et al. Development of a rubella vaccination strategy: contribution of a rubella susceptibility study of women of childbearing age in Kyrgyzstan, 2001. Clinical Infectious Diseases, 2004; 38:1780-3
15. Luman ET, et al. Comparison of two survey methodologies to assess vaccination coverage. International Journal of Epidemiology 2007; 36: 633-641.
16. World Health Organization. Manual for the virological investigation of polio. 1997 WHO EPI/GEN/97·01. EPV1, Expanded Program on Immunization.
17. World Health Organization. Report of a WHO informal consultation on polio neutralization antibody assays, Nashville, 5-6 December 1991, Geneva, 1991 (WHO/EPI/RD/91·3 Rev 1).
18. Kärber G. A contribution to the collective treatment of a pharmacological experimental series. Archiv für Experimentelle Pathologie und Pharmakologie 1931; 162: 480-483.
19. Cutts FT, Vynnycky E. Modeling the incidence of congenital rubella syndrome in developing countries. International Journal of Epidemiology 1999; 28: 1176-1184.
20. Shkedy Z, et al. Modelling age-dependent force of infection from prevalence data using fractional polynomials. Statistics in Medicine 2006; 25: 1577-1591.
21. Alleman M, et al. Factors contributing to outbreaks of wild poliovirus type 1 infection involving persons aged ≥15 years in the Democratic Republic of the Congo, 2010-2011, informed by a pre-outbreak poliovirus immunity assessment, Journal of Infectious Diseases (in press).
22. Green M, et al. Age differences in immunity against wild and vaccine strains of poliovirus prior to 1988 outbreak in Israel and response to booster immunization, Vaccine 1993; 11: 75-81.
23. Gidding H, et al. National serosurvey of poliovirus immunity in Australia, 1996-99. Australian and New Zealand Journal of Public Health 2005; 29: 48-52.
24. Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Eurosurveillance 2007; 12: 133-136.
25. Kiffer C, et al. Estimated prevalence of immunity to poliomyelitis in the city of São Paulo, Brazil: a population-based survey. Brazilian Journal of Infectious Diseases 2002; 6: 232-243.
26. Stark K, et al. Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine 1999; 153: 207-214.
27. Wang H, et al. Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China. Clinical and Vaccine Immunology 2013; 20: 1070-1075.
28. Thompson KM, et al. Modeling population immunity to support efforts to achieve eradication of wild polioviruses and maintain protection from infection. Risk Analysis 2013; 33: 647-63.
29. World Health Organization. Global polio eradication emergency action plan, 2012-2013. (http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/EAP-201205.pdf). Accessed 6 March 2014.
30. World Health Organization. Polio eradication and endgame strategic plan, 2013-2018. (http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP-EN-US.pdf). Accessed 6 March 2014.
31. Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. Journal of Infectious Diseases 2004; 189: S27-35.
32. Hutchins SS, et al. Population immunity to measles in the United States, 1999. Journal of Infectious Diseases 2004; 189: S91-S97.
33. de Melker H, et al. The seroepidemiology of measles in Western Europe. Epidemiology and Infection 2001; 126: 249-259.
34. Kumakura S, et al. Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy. Epidemiology and Infection 2014; 142: 12-19.
35. Liu Y, et al. Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among children. PLoS ONE 2013; 8: e66771.
36. World Health Organization. Guidelines for surveillance of congenital rubella syndrome (CRS) and rubella (http://whqlibdoc.who.int/hq/1999/WHO-V&B-99.22.pdf). Accessed 6 March 2014.
37. Cutts FT, et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bulletin of the World Health Organization 1997; 75: 55-68.
38. Centers for Disease Control and Prevention. Rubella and congenital rubella syndrome control and elimination - global progress, 2000-2012. Morbidity and Mortality Weekly Report 2013; 62: 983-986.
39. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 - conclusions and recommendations. Weekly Epidemiological Record 2014; 89: 1-20.